Filtered By:
Management: Funding
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 28 results found since Jan 2013.
Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort
EClinicalMedicine. 2023 Jul 21;62:102107. doi: 10.1016/j.eclinm.2023.102107. eCollection 2023 Aug.ABSTRACTBACKGROUND: Lack of specific definitions of clinical characteristics, disease severity, and risk and preventive factors of post-COVID-19 syndrome (PCS) severely impacts research and discovery of new preventive and therapeutics drugs.METHODS: This prospective multicenter cohort study was conducted from February 2020 to June 2022 in 5 countries, enrolling SARS-CoV-2 out- and in-patients followed at 3-, 6-, and 12-month from diagnosis, with assessment of clinical and biochemical features, antibody (Ab) response, Variant o...
Source: Cell Research - September 1, 2023 Category: Cytology Authors: Elisa Gentilotti Anna G órska Adriana Tami Roy Gusinow Massimo Mirandola Jes ús Rodríguez Baño Zaira R Palacios Baena Elisa Rossi Jan Hasenauer Iris Lopes-Rafegas Elda Righi Natascia Caroccia Salvatore Cataudella Zeno Pasquini Thomas Osmo Lidia Del Pi Source Type: research
Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial
Lancet Respir Med. 2023 Mar 21:S2213-2600(22)00534-3. doi: 10.1016/S2213-2600(22)00534-3. Online ahead of print.ABSTRACTBACKGROUND: The clinical value of using digital tools to assess adherence and lung function in uncontrolled asthma is not known. We aimed to compare treatment decisions guided by digitally acquired data on adherence, inhaler technique, and peak flow with existing methods.METHODS: A 32-week prospective, multicentre, single-blinded, parallel, randomly controlled trial was done in ten severe asthma clinics across Ireland, Northern Ireland, and England. Participants were 18 years or older, had uncontrolled as...
Source: Respiratory Care - March 24, 2023 Category: Respiratory Medicine Authors: Elaine Mac Hale Garrett Greene Christopher Mulvey Matshediso C Mokoka Job F M van Boven Breda Cushen Imran Sulaiman Vincent Brennan Patrick J Kerr Richard B Reilly Cian Hughes Brian D Kent David J Jackson Marcus Butler Ian Counihan James Hayes John Faul M Source Type: research
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials
This study was registered with PROSPERO, CRD42021257134.FINDINGS: Our search identified 857 records, yielding nine RCTs eligible for inclusion. Of these nine eligible RCTs, individual data were provided for eight, covering 10 480 patients hospitalised with COVID-19 (99% of such patients included in such RCTs worldwide) recruited between Feb 6, 2020, and April 1, 2021. Within 28 days of randomisation, 662 (12·5%) of 5317 patients assigned to remdesivir and 706 (14·1%) of 5005 patients assigned to no remdesivir died (adjusted odds ratio [aOR] 0·88, 95% CI 0·78-1·00, p=0·045). We found evidence for a credible subgroup e...
Source: Respiratory Care - February 24, 2023 Category: Respiratory Medicine Authors: Alain Amstutz Benjamin Speich France Mentr é Corina Silvia Rueegg Drifa Belhadi Lambert Assoumou Charles Burdet Srinivas Murthy Lori Elizabeth Dodd Yeming Wang Kari A O Tikkinen Florence Ader Maya Hites Maude Bouscambert Mary Anne Trabaud Mike Fralick To Source Type: research
End of year message from Cochrane ' s CEO, Catherine Spencer
Dear Cochrane Colleagues, Members and Supporters, Thank you to everyone across our community for your dedication and commitment to Cochrane during 2022. The last few years have at times felt tumultuous, both due to Covid and world events, but also because of the changes we are making to ensure that Cochrane is fit for a future that meets our vision of aworld of better health for all people, where decisions about health and care are informed by high-quality evidence. We are well on our way to creating an evolved impact-driven organisation to support evidence-based health and social care. With your help we are building on ...
Source: Cochrane News and Events - December 20, 2022 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial
This study aimed to assess whether rituximab is superior to cyclophosphamide as a treatment for severe or progressive CTD associated ILD.METHODS: We conducted a randomised, double-blind, double-dummy, phase 2b trial to assess the superiority of rituximab compared with cyclophosphamide. Patients aged 18-80 years with severe or progressive ILD related to scleroderma, idiopathic inflammatory myositis, or mixed CTD, recruited across 11 specialist ILD or rheumatology centres in the UK, were randomly assigned (1:1) to receive rituximab (1000 mg at weeks 0 and 2 intravenously) or cyclophosphamide (600 mg/m2 body surface area ever...
Source: Respiratory Care - November 14, 2022 Category: Respiratory Medicine Authors: Toby M Maher Veronica A Tudor Peter Saunders Michael A Gibbons Sophie V Fletcher Christopher P Denton Rachel K Hoyles Helen Parfrey Elisabetta A Renzoni Maria Kokosi Athol U Wells Deborah Ashby Matyas Szigeti Philip L Molyneaux RECITAL Investigators Source Type: research
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis
Lancet Respir Med. 2022 Apr 7:S2213-2600(22)00002-9. doi: 10.1016/S2213-2600(22)00002-9. Online ahead of print.ABSTRACTBACKGROUND: Community-based clinical trials of the inhaled corticosteroid budesonide in early COVID-19 have shown improved patient outcomes. We aimed to understand the inflammatory mechanism of budesonide in the treatment of early COVID-19.METHODS: The STOIC trial was a randomised, open label, parallel group, phase 2 clinical intervention trial where patients were randomly assigned (1:1) to receive usual care (as needed antipyretics were only available treatment) or inhaled budesonide at a dose of 800 μg ...
Source: Respiratory Care - April 10, 2022 Category: Respiratory Medicine Authors: Jonathan R Baker Mahdi Mahdi Dan V Nicolau Sanjay Ramakrishnan Peter J Barnes Jodie L Simpson Steven P Cass Richard E K Russell Louise E Donnelly Mona Bafadhel Source Type: research
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
Lancet Respir Med. 2022 Feb 3:S2213-2600(22)00006-6. doi: 10.1016/S2213-2600(22)00006-6. Online ahead of print.ABSTRACTBACKGROUND: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in patients with confirmed SARS-CoV-2 infection. We aimed to evaluate the efficacy and safety of baricitinib plus standard of care in critically ill hospitalised adults with COVID-19 requiring invasive mechanical ventilation or extracorporeal membran...
Source: Respiratory Care - February 6, 2022 Category: Respiratory Medicine Authors: E Wesley Ely Athimalaipet V Ramanan Cynthia E Kartman Stephanie de Bono Ran Liao Maria Lucia B Piruzeli Jason D Goldman Jos é Francisco Kerr Saraiva Sujatro Chakladar Vincent C Marconi COV-BARRIER Study Group Source Type: research
Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial
This study is registered with the International Standard Randomised Controlled Trial Registry, ISRCTN67875351.FINDINGS: Between June 22, 2017, and Aug 8, 2019, 535 children were assessed for eligibility, 20 were ineligible and six were excluded post-randomisation. 509 children were recruited and at baseline, the mean age of participants was 10·1 years (SD 2·6), and 308 (60·5%) were male. The median FeNO was 21 ppb (IQR 10-48), mean predicted FEV1 was 89·6% (SD 18·0), and median daily dose of inhaled corticosteroids was 400 μg budesonide equivalent (IQR 400-1000). Asthma was partly or fully controlled in 256 (50·3%) ...
Source: Respiratory Care - February 1, 2022 Category: Respiratory Medicine Authors: Steve Turner Seonaidh Cotton Jessica Wood Victoria Bell Edwin-Amalraj Raja Neil W Scott Heather Morgan Louisa Lawrie David Emele Charlotte Kennedy Graham Scotland Shona Fielding Graeme MacLennan John Norrie Mark Forrest Erol A Gaillard Johan de Jongste Ma Source Type: research
Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study
Lancet Respir Med. 2022 Jan 13:S2213-2600(21)00543-9. doi: 10.1016/S2213-2600(21)00543-9. Online ahead of print.ABSTRACTBACKGROUND: There is considerable uncertainty over whether adults with asthma should be offered booster vaccines against SARS-CoV-2 and, if so, who should be prioritised for booster vaccination. We were asked by the UK's Joint Commission on Vaccination and Immunisation to undertake an urgent analysis to identify which adults with asthma were at an increased risk of serious COVID-19 outcomes to inform deliberations on booster COVID-19 vaccines.METHODS: This national incident cohort study was done in all ad...
Source: Respiratory Care - January 16, 2022 Category: Respiratory Medicine Authors: Ting Shi Jiafeng Pan Eleftheria Vasileiou Chris Robertson Aziz Sheikh Public Health Scotland and the EAVE II Collaborators Source Type: research
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial
This study is registered with the Netherlands Trial Register, NTR4978, and is ongoing.FINDINGS: Between Feb 15, 2015, and Aug 27, 2019, 371 patients were screened for eligibility, of whom 238 were eligible, willing to participate, and randomly assigned to ESS plus medical therapy (n=121) or medical therapy (n=117) and 234 were included in the baseline ITT population (n=118 ESS plus medical therapy; n=116 medical therapy). 142 (61%) of 234 patients at baseline were men and 92 (39%) were women, and the mean age was 50·4 years (SD 12·7). 206 participants were analysed at 12 months for the primary outcome (n=103 in the ESS p...
Source: Respiratory Care - January 11, 2022 Category: Respiratory Medicine Authors: Evelijn S Lourijsen Sietze Reitsma Marleen Vleming Gerjon Hannink Gwijde F J P M Adriaensen Marjolein E Cornet D Rienk Hoven Ward J M Videler Jochen H Bretschneider Susanne M Reinartz Maroeska M Rovers Wytske J Fokkens Source Type: research
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Lancet Respir Med. 2021 Dec 1:S2213-2600(21)00494-X. doi: 10.1016/S2213-2600(21)00494-X. Online ahead of print.ABSTRACTBACKGROUND: The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is among cytokines that contribute to the inflammatory processes. Lenzilumab, a GM-CSF neutralising monoclonal antibody, was investigated in the LIVE-AIR trial to assess its efficacy and safety in treating COVID-19 beyond available treatments.METHODS: In LIVE-AIR, a phase 3, randomised, double-blind, ...
Source: Respiratory Care - December 5, 2021 Category: Respiratory Medicine Authors: Zelalem Temesgen Charles D Burger Jason Baker Christopher Polk Claudia R Libertin Colleen F Kelley Vincent C Marconi Robert Orenstein Victoria M Catterson William S Aronstein Cameron Durrant Dale Chappell Omar Ahmed Gabrielle Chappell Andrew D Badley LIVE Source Type: research
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
This study is registered with ClinicalTrials.gov, NCT02320058.FINDINGS: Between Feb 19, 2015, and Nov 1, 2017, 119 (72%) of 165 screened patients were enrolled and treated: 101 patients were asymptomatic (cohort A; median follow-up 34·3 months [IQR 14·7-36·4]) and 18 were symptomatic (cohort B; median follow-up 7·5 months [1·2-35·2]). Investigator-assessed intracranial clinical benefit was observed in 58 (57·4% [95% CI 47·2-67·2]) of 101 patients in cohort A and three (16·7% [3·6-41·4]) of 18 patients in cohort B; investigator-assessed objective response was observed in 54 (53·5% [43·3-63·5]) patients in coh...
Source: Ann Oncol - November 14, 2021 Category: Cancer & Oncology Authors: Hussein A Tawbi Peter A Forsyth F Stephen Hodi Alain P Algazi Omid Hamid Christopher D Lao Stergios J Moschos Michael B Atkins Karl Lewis Michael A Postow Reena P Thomas John Glaspy Sekwon Jang Nikhil I Khushalani Anna C Pavlick Marc S Ernstoff David A Re Source Type: research
